Literature DB >> 21976403

¹H NMR-based metabolomic study of metabolic profiling for systemic lupus erythematosus.

X Ouyang1, Y Dai, J L Wen, L X Wang.   

Abstract

Systemic lupus erythematosus (SLE) is a chronic inflammatory disease characterized by multi-system involvement, diverse clinical presentation, and alterations in circulating metabolites. In this study, a (1)H NMR spectroscopy-based metabolomics approach was applied to establish a human SLE serum metabolic profile. Serum samples were obtained from patients with SLE (n = 64), patients with rheumatoid arthritis (RA) (n = 30) and healthy controls (n = 35). The NOESYPR1D spectrum combined with multi-variate pattern recognition analysis was used to cluster the groups and establish a disease-specific metabolites phenotype. Principal component analysis (PCA) and orthogonal partial least-squares discriminant analysis (OPLS-DA) models were capable of distinguishing SLE or RA patients from healthy subjects. The OPLS-DA model was able to predict diagnosis of SLE with a sensitivity rate of 60.9% and a specificity rate of 97.1%. For diagnosing RA, the model has much higher sensitivity (96.7%) and specificity (91.4%). The SLE serum samples were characterized by reduced concentrations of valine, tyrosine, phenylalanine, lysine, isoleucine, histidine, glutamine, alanine, citrate, creatinine, creatine, pyruvate, high-density lipoprotein, cholesterol, glycerol, formate and increased concentrations of N-acetyl glycoprotein, very low-density lipoprotein and low-density lipoprotein in comparison with the control population. The results not only indicated that serum NMR-based metabolomic methods had sufficient sensitivity and specificity to distinguish SLE and RA from healthy controls, but also have the potential to be developed into a clinically useful diagnostic tool, and could also contribute to a further understanding of disease mechanisms.

Entities:  

Mesh:

Year:  2011        PMID: 21976403     DOI: 10.1177/0961203311418707

Source DB:  PubMed          Journal:  Lupus        ISSN: 0961-2033            Impact factor:   2.911


  36 in total

1.  Connective tissue diseases: Promises and challenges of metabolomics in SLE.

Authors:  Huihua Ding; Chandra Mohan
Journal:  Nat Rev Rheumatol       Date:  2016-10-06       Impact factor: 20.543

2.  Analysis of the free fatty acid metabolome in the plasma of patients with systemic lupus erythematosus and fever.

Authors:  Tae Hwan Shin; Hyoun-Ah Kim; Ju-Yang Jung; Wook-Young Baek; Hyeon-Seong Lee; Hyung Jin Park; Jeuk Min; Man-Jeong Paik; Gwang Lee; Chang-Hee Suh
Journal:  Metabolomics       Date:  2017-12-14       Impact factor: 4.290

3.  NMR based serum metabolomics reveals a distinctive signature in patients with Lupus Nephritis.

Authors:  Anupam Guleria; Avadhesh Pratap; Durgesh Dubey; Atul Rawat; Smriti Chaurasia; Edavalath Sukesh; Sanat Phatak; Sajal Ajmani; Umesh Kumar; Chunni Lal Khetrapal; Paul Bacon; Ramnath Misra; Dinesh Kumar
Journal:  Sci Rep       Date:  2016-10-14       Impact factor: 4.379

Review 4.  Metabolomics approach in allergic and rheumatic diseases.

Authors:  Rossana Scrivo; Luca Casadei; Mariacristina Valerio; Roberta Priori; Guido Valesini; Cesare Manetti
Journal:  Curr Allergy Asthma Rep       Date:  2014-06       Impact factor: 4.806

5.  Critical review of reporting of the data analysis step in metabolomics.

Authors:  E C Considine; G Thomas; A L Boulesteix; A S Khashan; L C Kenny
Journal:  Metabolomics       Date:  2017-12-01       Impact factor: 4.290

Review 6.  Metabolic determinants of lupus pathogenesis.

Authors:  Xiangyu Teng; Josephine Brown; Seung-Chul Choi; Wei Li; Laurence Morel
Journal:  Immunol Rev       Date:  2020-03-12       Impact factor: 12.988

7.  Systemic lupus erythematosus diagnostics in the 'omics' era.

Authors:  Cristina Arriens; Chandra Mohan
Journal:  Int J Clin Rheumtol       Date:  2013-12-01

Review 8.  Diagnostic and prognostic tests in systemic lupus erythematosus.

Authors:  Natalia Vasquez-Canizares; Dawn Wahezi; Chaim Putterman
Journal:  Best Pract Res Clin Rheumatol       Date:  2017-11-06       Impact factor: 4.098

9.  Metabolites as biomarkers of adverse reactions following vaccination: A pilot study using nuclear magnetic resonance metabolomics.

Authors:  Bruce M McClenathan; Delisha A Stewart; Christina E Spooner; Wimal W Pathmasiri; Jason P Burgess; Susan L McRitchie; Y Sammy Choi; Susan C J Sumner
Journal:  Vaccine       Date:  2017-02-03       Impact factor: 3.641

Review 10.  Metabolomics in rheumatic diseases: desperately seeking biomarkers.

Authors:  Monica Guma; Stefano Tiziani; Gary S Firestein
Journal:  Nat Rev Rheumatol       Date:  2016-03-03       Impact factor: 20.543

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.